Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK centre seeks wider pre-implantation testing:

This article was originally published in Clinica

Executive Summary

London's Bridge Fertility, Gynaecology and Genetics Centre is planning to apply for a licence to use isothermal whole genome amplification in pre-implantation testing. It says that the technique would enable it to screen for "hundreds of conditions" within days of fertilisation. At present, pre-implantation genetic screening, which is regulated by the Human Fertilisation and Embryology Authority (HFEA), can only be performed on a small number of disorders, such as cystic fibrosis, muscular dystrophy and haemophilia. "Centres must submit an application to the HFEA for each new condition for which they wish to test and for each new test that they wish to use," according to current HFEA guidelines, issued in 2001.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts